Mithra CEO David Horn Solomon stated that the company intends to seek a partnership to market Donesta in the US. Image Credit: i viewfinder / Shutterstock.

Mithra Pharmaceuticals and Searchlight Pharma have entered a licensing agreement for Donesta, an investigational drug for treating menopausal symptoms.

The agreement grants Searchlight exclusive sales and marketing rights in Canada.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As per the agreement, Searchlight is responsible for regulatory approval of Donesta in Canada while Mithra would be entitled to licensing fees, Canadian sales royalties, and milestone-based payments totalling up to €17.05m ($18.8m).

Donesta is an orally administered estetrol (E4) hormone therapy that targets nuclear estrogen receptor alpha (ERα) and can potentially avoid the common side effects associated with hormonal therapies.

Mithra’s first estertrol (E4) therapy was a combination therapy Estelle (15mg estetrol and 3mg drospirenone), which is currently marketed in the US, Canada, and Europe.

See Also:

The data from the two multicentre, randomised Phase III trials (C301 – NCT04209543, and C302 – NCT04090957) evaluating Donesta, demonstrated a reduction in vasomotor symptoms from baseline and compared to placebo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Mithra has reported positive safety data in North America in the C302 Phase III trial, with primary safety data from Europe expected in H1 2024.

Mithra plans to file marketing authorisation with the US Food and Drug Administration (FDA) by the end of 2023, based on the safety and efficacy data from the C302 Phase III trial. Searchlight also plans to file for marketing authorisation with Health Canada in H1 2024.

Mithra has previously signed agreements with Searchlight for the licensing of an oral contraceptive Nextstellis (drospirenone and estetrol tablets), and a vaginal contraceptive Haloette, in Canada in 2021 and 2022, respectively.

Mithra CEO David Horn Solomon stated that the company intends to seek a partnership to market Donesta in the US.

Apart from the contraceptive and hormone therapy, Mithra is also developing a colony-stimulating factor 1 receptor (CSF-1R) kinase inhibitor with BCI Pharma for treating endometriosis, and certain oncology indications and inflammatory disorders.